Prognostic significance of programmed cell death-ligand 1 expression on immune cells and epithelial-mesenchymal transition expression in patients with hepatocellular carcinoma

被引:0
|
作者
Jung, Hae Il [1 ]
Ahn, Hyein [2 ]
Oh, Mee-Hye [2 ]
Yun, JongHyuk [1 ]
Lee, Hyunyong [1 ]
Bae, Sang Ho [1 ]
Kim, Yung Kil [1 ]
Kim, Sung Yong [1 ]
Baek, Moo-Jun [1 ]
Lee, Moon-Soo [1 ]
机构
[1] Soonchunhyang Univ, Cheonan Hosp, Coll Med, Dept Surg, 31 Suncheonhyang 6 gil, Cheonan 31151, South Korea
[2] Soonchunhyang Univ, Cheonan Hosp, Coll Med, Dept Pathol, Cheonan, South Korea
基金
新加坡国家研究基金会;
关键词
Epithelial-mesenchymal transition; Hepatocellular carcinoma; Prognosis; Programmed cell death 1 ligand 2 protein; Tumor-infiltrating lymphocytes; PD-L1; EXPRESSION; POOR SURVIVAL; INFILTRATION;
D O I
10.4174/astr.2023.105.5.297
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: Immune checkpoint inhibitors (ICIs) have been shown significant oncological improvements in several cancers. However, ICIs are still in their infancy in hepatocellular carcinoma (HCC). Programmed cell death-ligand 1 (PD-L1), tumorinfiltrating cytes (TILs), and epithelial-mesenchymal transition (EMT) have been known as prognostic factors in HCC. Therefore, we have focused on identifying the molecular mechanisms between each marker to evaluate a predictive role. Methods: Formalin-fixed paraffin-embedded samples were obtained from 166 patients with HCC who underwent surgery. The expression of PD-L1 and TILs and EMT marker were evaluated by immunohistochemical analysis. Results: The multivariate analysis showed that TIL expression (hazard ratio [HR], 0.483; 95% confidence interval [CI], 0.269-0.866; P = 0.015) were independent prognostic factors for overall survival. The prognostic factors for disease-free survival were EMT marker expression (HR, 1.565; 95% CI, 1.019-2.403; P = 0.005). Patients with high expression of TILs had significantly better survival compared to patients with low expression (P = 0.023). Patients who were TIL+/EMT- showed a significantly better prognosis than those who were TIL-/EMT+ (P = 0.049). Conclusion: This study demonstrates that PD-L1 expression of TILs is closely associated with EMT marker expression in HCC. Clinical
引用
收藏
页码:297 / 309
页数:13
相关论文
共 50 条
  • [31] Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer
    Koganemaru, Shigehiro
    Inoshita, Naoko
    Miura, Yuji
    Miyama, Yu
    Fukui, Yudai
    Ozaki, Yukinori
    Tomizawa, Kenji
    Hanaoka, Yutaka
    Toda, Shigeo
    Suyama, Koichi
    Tanabe, Yuko
    Moriyama, Jin
    Fujii, Takeshi
    Matoba, Shuichiro
    Kuroyanagi, Hiroya
    Takano, Toshimi
    CANCER SCIENCE, 2017, 108 (05) : 853 - 858
  • [32] Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
    Motohide Uemura
    Noboru Nakaigawa
    Naoto Sassa
    Katsunori Tatsugami
    Kenichi Harada
    Toshinari Yamasaki
    Nobuaki Matsubara
    Takuya Yoshimoto
    Yuki Nakagawa
    Tamaki Fukuyama
    Mototsugu Oya
    Nobuo Shinohara
    Hirotsugu Uemura
    Toyonori Tsuzuki
    International Journal of Clinical Oncology, 2021, 26 : 2073 - 2084
  • [33] Programmed death-ligand expression and lymph nodeinvolvement in penile squamous cell carcinoma
    Peyroteo, Ines
    Santos, Filipa
    Marialva, Celso
    Ramos, Rodrigo
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2024, 96 (03)
  • [34] Heterogeneity of programmed cell death-ligand 1 expression in lung cancer
    Mansfield, Aaron
    Murphy, Stephen
    Peikert, Tobias
    Vasmatzis, George
    Wigle, Dennis
    Aubry, Marie Christine
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S31 - S32
  • [35] Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma
    Min, Aung Kyi Thar
    Okayama, Hirokazu
    Saito, Motonobu
    Ashizawa, Mai
    Aoto, Keita
    Nakajima, Takahiro
    Saito, Katsuharu
    Hayase, Suguru
    Sakamoto, Wataru
    Tada, Takeshi
    Hanayama, Hiroyuki
    Saze, Zenichirou
    Momma, Tomoyuki
    Ohki, Shinji
    Sato, Yusuke
    Motoyama, Satoru
    Mimura, Kosaku
    Kono, Koji
    CANCER MEDICINE, 2018, 7 (07): : 3321 - 3330
  • [36] Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma
    Yokoyama, Shintaro
    Miyoshi, Hiroaki
    Nakashima, Kazutaka
    Shimono, Joji
    Hashiguchi, Toshihiro
    Mitsuoka, Masahiro
    Takamori, Shinzo
    Akagi, Yoshito
    Ohshima, Koichi
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4727 - 4734
  • [37] Programmed death-ligand 1 expression in rectal cancer
    Jomrich, G.
    Silberhumer, G. R.
    Marian, B.
    Beer, A.
    Muellauer, L.
    EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA, 2016, 48 (06): : 352 - 356
  • [38] Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis
    Ouyang, Yushu
    Liu, Wendao
    Zhang, Ningning
    Yang, Xiaobing
    Li, Jinwei
    Long, Shunqin
    CANCER MEDICINE, 2021, 10 (20): : 7021 - 7039
  • [39] Status of programmed death-ligand 1 expression in sarcomas
    Park, Hyung Kyu
    Kim, Mingi
    Sung, Minjung
    Lee, Seung Eun
    Kim, Yu Jin
    Choi, Yoon-La
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [40] The Prognostic Role of Programmed Death-Ligand 1 in Nasopharyngeal Carcinoma
    Wotman, Michael
    Herman, Saori W.
    Costantino, Peter
    Tham, Tristan
    LARYNGOSCOPE, 2020, 130 (11): : 2598 - 2606